Overactive bladder

BlueWind Medical Appoints Dr. Liz Kwo to Board of Directors

Retrieved on: 
Tuesday, September 27, 2022

PARK CITY, Utahand HERZLIYA,Israel, Sept.27, 2022 /PRNewswire/ -- BlueWind Medical, Ltd., a medical device company working to transform neuromodulation therapy for overactive bladder (OAB), announced today that Liz Kwo, M.D., MBA, MPH, Chief Medical Officer at Everly Health, has joined the company's Board of Directors.

Key Points: 
  • PARK CITY, Utahand HERZLIYA,Israel, Sept.27, 2022 /PRNewswire/ -- BlueWind Medical, Ltd., a medical device company working to transform neuromodulation therapy for overactive bladder (OAB), announced today that Liz Kwo, M.D., MBA, MPH, Chief Medical Officer at Everly Health, has joined the company's Board of Directors.
  • "I am pleased to join BlueWind Medical at this exciting phase and supportthe company's mission to revolutionize neuromodulation therapy for overactive bladder."
  • "Dr. Kwo is a distinguished physician, leader, and entrepreneur with extensive knowledge in building and scaling healthcare products to improve outcomes and quality care," said Dan Lemaitre, Chairman and CEO of BlueWind Medical.
  • BlueWind Medical is an innovative medical device company that is transforming neuromodulation therapy for the treatment of Overactive Bladder (OAB).

PM360 Magazine Announces Winners of 2022 Trailblazer Awards

Retrieved on: 
Friday, September 23, 2022

NEW YORK, Sept. 23, 2022 /PRNewswire/ -- PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022. The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries. In total, 72 winners were named across eight overall categories: Companies of the Year, CEOs of the Year, Products of the Year, Marketer of the Year, Marketing Team of the Year, Lifetime Achievement, Brand Champions, and Initiatives.

Key Points: 
  • NEW YORK, Sept. 23, 2022 /PRNewswire/ -- PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022.
  • The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries.
  • Each of the winners were judged and selected by the PM360 Editorial Advisory Board, a cross section of experts from across the industry.
  • PM360 will publish profiles of this year's Trailblazer winners in its October issue and on its website.

Sandoz Canada continues to expand its portfolio of generic products

Retrieved on: 
Wednesday, September 21, 2022

PrSandoz Apixaban SDZ is an important generic equivalent; the market for this product has been growing for the past five years in Canada.

Key Points: 
  • PrSandoz Apixaban SDZ is an important generic equivalent; the market for this product has been growing for the past five years in Canada.
  • BOUCHERVILLE, Quebec, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Sandoz Canada Inc. is proud to announce the launch of several products that will expand its portfolio of high-quality generics.
  • Sandoz Canada is committed to its role in the healthcare sector and our teams are constantly working to expand our product portfolio to improve patient access to affordable, high-quality medicines.
  • Our products will generate substantial savings that can be reinvested for the benefit of Canadians, says Michel Robidoux, President and General Manager of Sandoz Canada.

GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases

Retrieved on: 
Wednesday, September 14, 2022

CAMBRIDGE, Mass., Sept. 14, 2022 /PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmunity, autoinflammation and allergic diseases, today announced an upcoming presentation of preclinical data relating to the company's platform technology. The abstract, entitled "Finely Controlled IL-2 Signal in Engineered Human Tregs utilizing a Chemically Induced Signaling Complex (CISC)" will be presented at The Promise of IL-2 Conference in Paris, France on September 16, 2022.

Key Points: 
  • By way of background, Tregsare crucially important in addressing many diseases driven by uncontrolled autologous and allogeneic reactivity.
  • Further, interleukin-2 (IL-2) is the key cytokine for supporting Tregs homeostasis and its functional scarcity underpins many autoimmune diseases.
  • For Tregs therapeutics, IL-2 is essential to support in vivo Tregs stability, proliferation, and persistence, and hence, potency.
  • The company also has a collaboration with Bristol Myers Squibb for the development of Treg therapies for inflammatory bowel diseases.

Urovant Sciences® Receives “Best in Category” Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022 International Continence Society Conference

Retrieved on: 
Thursday, September 8, 2022

The award-winning abstract was presented at the 2022 International Continence Society annual meeting on September 8, 2022.

Key Points: 
  • The award-winning abstract was presented at the 2022 International Continence Society annual meeting on September 8, 2022.
  • The 2022 ICS Annual meeting is being held September 7-10, 2022, in a hybrid format with both online and in person participation (Vienna, Austria).
  • The podium presentation at ICS 2022 took place on Thursday, September 8, at 10:20 Central European Time (CET).
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System

Retrieved on: 
Thursday, September 8, 2022

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15, the companys newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15, the companys newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.
  • The Axonics F15 received regulatory approval from Health Canada following U.S. FDA approval.
  • The approval of the Axonics recharge-free system is welcome news for patients in Canada suffering from bladder and bowel dysfunction, said Gary J.
  • Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy.

Urovant Sciences® Named 17th on the List of Fortune® Best Workplaces in BioPharma™ (2022)

Retrieved on: 
Wednesday, September 7, 2022

Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma .

Key Points: 
  • Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma .
  • Its an honor to be recognized by Fortune and Great Place to Work, said James Robinson, CEO of Urovant Sciences.
  • The Fortune Best Workplaces in BioPharma list is highly competitive.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo and Powered by People and Possibilities are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

NEUSPERA MEDICAL® APPOINTS STEFFEN HOVARD AS CEO

Retrieved on: 
Tuesday, September 6, 2022

SAN JOSE, Calif., Sept. 6, 2022 /PRNewswire/ -- Neuspera® Medical, a medical device company developing implantable medical device technology for patients with chronic illness, today announced the hiring of seasoned medtech executive, Steffen Hovard as Chief Executive Officer. He joins as the company recently began enrollment of the second phase of its U.S. pivotal clinical trial (SANS-UUI). The study will evaluate the safety and efficacy of Neuspera's Nuvella™ system designed to treat patients with urinary urgency incontinence (UUI), which is a symptom of overactive bladder (OAB).

Key Points: 
  • SAN JOSE, Calif., Sept. 6, 2022 /PRNewswire/ -- Neuspera Medical, a medical device company developing implantable medical device technology for patients with chronic illness, today announced the hiring of seasoned medtech executive, Steffen Hovard as Chief Executive Officer.
  • Steffen also serves as a board member for several companies in the medical device industry.
  • "I am excited to join Neuspera at this important time as the company builds momentum and clinical evidence for the Nuvella system," stated Steffen Hovard, CEO of Neuspera Medical.
  • Neuspera Medical, Inc. is committed to developing implantable medical devices that will improve the lives of patients battling chronic illnesses.

Cosmetic Surgery Global Market to Reach $48.84 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022

North America was the largest region in the cosmetic surgery market in 2021 and is expected to be the fastest-growing region in the forecast period.

Key Points: 
  • North America was the largest region in the cosmetic surgery market in 2021 and is expected to be the fastest-growing region in the forecast period.
  • The regions covered in the cosmetic surgery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
  • The rising number of cosmetic surgery hospitals is driving the growth of the cosmetic surgery market.
  • The increasing number of cosmetic surgery has raised the number of hospitals, free-standing ambulatory surgical facilities, and office premises to conduct cosmetic surgery procedures.

Colin P. Ryan, M.D., Joins Central Ohio Urology Group

Retrieved on: 
Monday, August 22, 2022

Corina Tracy, Chief Executive Officer of U.S. Urology Partners , the parent company of Central Ohio Urology Group , stated, We are pleased to welcome Dr. Colin Ryan to the care team at Central Ohio Urology Group.

Key Points: 
  • Corina Tracy, Chief Executive Officer of U.S. Urology Partners , the parent company of Central Ohio Urology Group , stated, We are pleased to welcome Dr. Colin Ryan to the care team at Central Ohio Urology Group.
  • Dr. Ryan said, I feel at home with the staff at Central Ohio Urology Group , who I know work hard to ensure the best care for patients.
  • To learn more about Dr. Colin P. Ryan or to schedule an appointment with the Central Ohio Urology Group care team , please visit www.centralohiourology.com or call (614) 396-2684.
  • Headquartered just outside of Columbus in Gahanna, Ohio, Central Ohio Urology Group provides comprehensive services , including general urology , mens health , womens health , cancer care , advanced cancer treatment and radiation oncology .